Lisinopril in Black and African Ancestry Patients: Safety Profile Differences Explained

Why Lisinopril Responds Differently by Ancestry

ACE inhibitors like lisinopril work by blocking the conversion of angiotensin I to angiotensin II and by reducing bradykinin degradation. The latter mechanism is central to why the drug behaves differently across ancestral populations. Black and African ancestry patients tend to have lower baseline renin activity, which reduces the drug's antihypertensive effect as monotherapy, and higher baseline bradykinin accumulation, which raises angioedema risk.

Renin-Angiotensin System Differences

Population-level studies consistently show that hypertension in Black patients is more often low-renin, volume-dependent hypertension. A 2014 pharmacogenomic analysis published in Hypertension confirmed that plasma renin activity predicts ACE-inhibitor response across ancestries, with lower renin predicting attenuated response 1. Because lisinopril primarily interrupts an angiotensin-II-driven pathway, patients with low renin activity experience a smaller pressure drop from ACE inhibition alone.

ACE Insertion/Deletion Polymorphism

The ACE gene insertion/deletion (I/D) polymorphism at intron 16 alters circulating ACE levels by roughly 50% between DD and II genotypes. PharmGKB annotates this variant (rs4646994) as a Level 2B pharmacogenomic biomarker for ACE-inhibitor response 2. The DD genotype frequency is approximately 25 to 30% in West African-ancestry populations versus 35 to 45% in European-ancestry populations, meaning a larger proportion of Black patients carry the II genotype associated with lower ACE activity and reduced drug target engagement 3.

Bradykinin Clearance and Cough Frequency

Lisinopril inhibits kininase II, the enzyme responsible for degrading bradykinin. Accumulated bradykinin stimulates sensory C-fibers in the bronchial mucosa, producing the characteristic dry cough in approximately 10 to 15% of all ACE-inhibitor users. Cough rates in Black patients are reported at 14 to 20% in prospective cohort data, compared with 8 to 12% in white patients 4. A single bradykinin-degradation pathway difference does not fully account for this gap; XPNPEP2 gene variants that encode aminopeptidase P, a secondary bradykinin-clearing enzyme, are more prevalent in Black individuals and independently predict ACE-inhibitor cough 5.

Angioedema: The Most Serious Safety Signal

Angioedema is the highest-severity adverse event associated with ACE-inhibitor use. Black patients experience it at rates 3 to 5 times higher than white patients. This is not a minor statistical footnote.

Incidence Data

A 2008 pharmacoepidemiology study in Archives of Internal Medicine (now JAMA Internal Medicine) analyzing over 12,000 ACE-inhibitor users found angioedema incidence of 0.68% in Black patients versus 0.15% in white patients over 12 months of follow-up 6. A subsequent 2011 analysis of Veterans Affairs data (N=33,821 new ACE-inhibitor users) reported similar findings: adjusted incidence rate ratio of 3.0 (95% CI 2.5 to 3.6) for Black versus white patients 7.

Mechanism Behind the Disparity

The XPNPEP2 variant mentioned above explains a portion of this risk, but genome-wide association data suggest additional loci. A 2019 GWAS published in PLOS Genetics identified variants in PRKCQ and BDKRB2 (the bradykinin B2 receptor gene) as associated with ACE-inhibitor angioedema, with some variants showing higher minor-allele frequencies in African-ancestry populations 8.

Clinical Presentation and Timeline

Angioedema from ACE inhibitors most often affects the lips, tongue, and oropharynx. The FDA label for lisinopril (Prinivil, Zestril) carries a black-box warning for this reaction. Angioedema may occur months to years after drug initiation, not only in the first weeks 9. Clinicians should counsel Black patients explicitly about this delayed-onset possibility. Any new oropharyngeal swelling in a patient on lisinopril warrants immediate discontinuation and emergency evaluation.

Blood Pressure Efficacy: ALLHAT and Ethnicity-Stratified Data

The ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) is the largest head-to-head antihypertensive trial ever conducted, with 33,357 participants followed for a mean of 4.9 years.

ALLHAT Black Subgroup Results

Of the 33,357 participants enrolled, 15,080 (approximately 45%) were Black. In this subgroup, patients randomized to lisinopril had a 40% higher rate of fatal and nonfatal stroke compared with those randomized to chlorthalidone (RR 1.40, 95% CI 1.17 to 1.68) 10. The lisinopril arm also showed a 19% higher rate of combined cardiovascular events in Black participants. Blood pressure in the lisinopril arm was on average 4 mmHg higher systolic than in the chlorthalidone arm within this subgroup, which largely explains the outcomes gap.

What ALLHAT Does Not Mean

ALLHAT does not show that lisinopril is harmful to Black patients in an absolute sense. The trial shows it is inferior to chlorthalidone as monotherapy for preventing stroke in this population. The 2002 JAMA report explicitly states: "Thiazide-type diuretics should be preferred for first-step antihypertensive therapy." 10 Lisinopril still reduced cardiovascular events versus placebo in both Black and non-Black participants; the comparison is head-to-head against a better-performing agent.

Combination Therapy Closes the Gap

Adding a thiazide-type diuretic or a calcium-channel blocker to lisinopril largely neutralizes the monotherapy BP-response difference. The ACCOMPLISH trial (N=11,506) showed that combination benazepril plus amlodipine reduced cardiovascular events more than benazepril plus hydrochlorothiazide, and subgroup analyses did not show a differential harm signal in Black participants for the ACE inhibitor component when used in combination 11.

Current Guideline Recommendations

AHA/ACC 2017 Hypertension Guideline

The 2017 AHA/ACC guideline (published in Hypertension and JACC) gives a Class I recommendation for thiazide diuretics or calcium-channel blockers as first-line antihypertensive therapy in Black patients without chronic kidney disease or heart failure with reduced ejection fraction 12. The guideline states: "In Black adults with hypertension but without HF or CKD, including those with diabetes mellitus, a thiazide-type diuretic or CCB is recommended as initial therapy." ACE inhibitors and ARBs drop to second-tier status for uncomplicated hypertension in this population specifically.

CKD and Proteinuria: Where Lisinopril Retains Priority

The picture changes when proteinuric CKD or diabetic nephropathy is present. The AASK trial (African American Study of Kidney Disease and Hypertension, N=1,094) demonstrated that ramipril (an ACE inhibitor) slowed GFR decline significantly more than amlodipine or metoprolol in Black patients with hypertensive CKD (GFR decline: 2.02 vs. 3.81 mL/min per 1.73 m2 per year, P<0.001) 13. Kidney Disease Improving Global Outcomes (KDIGO) 2021 guidelines endorse ACE inhibitor or ARB use for all patients with diabetes and albuminuria (urine albumin-creatinine ratio over 30 mg/g) regardless of ancestry 14.

The clinical decision logic for lisinopril prescribing in Black and African ancestry patients can therefore be framed as a two-pathway approach:

• No proteinuric CKD, no HFrEF: Start with chlorthalidone 12.5 to 25 mg/day or amlodipine 5 to 10 mg/day. Add lisinopril 10 to 40 mg/day if BP target not reached.
• Proteinuric CKD (UACR over 30 mg/g) or HFrEF: Lisinopril is first-line regardless of ancestry. Titrate to the highest tolerated dose (up to 40 mg/day for hypertension, up to 40 mg/day for HF per ACC/AHA HF guidelines).

Pharmacogenomics Beyond the ACE Gene

XPNPEP2 Variants

The XPNPEP2 gene on chromosome Xq25 encodes aminopeptidase P, which degrades bradykinin alongside kininase II. A promoter variant (c.-2399A>C) reduces aminopeptidase P activity and was associated with ACE-inhibitor angioedema with an odds ratio of 4.8 in Black men in a prospective study published in NEJM in 2002 5. This variant is substantially more common in individuals of African ancestry than European ancestry.

BDKRB2 Receptor Polymorphism

The bradykinin B2 receptor gene (BDKRB2) carries a functional insertion/deletion polymorphism (plus9/minus9) at exon 1. The minus9 allele, which increases receptor expression, shows higher frequency in some African-ancestry populations and may amplify the bradykinin-driven adverse effects of ACE inhibition 8. Routine genotyping is not yet standard of care, but PharmGKB lists this locus as relevant context for ACE-inhibitor safety monitoring 2.

G6PD Prevalence: Indirect but Clinically Relevant

G6PD deficiency affects approximately 10 to 14% of Black males and 1 to 2% of Black females in the United States 15. Lisinopril itself does not trigger hemolysis in G6PD-deficient patients and has no pharmacokinetic interaction with the enzyme. The clinical relevance arises when lisinopril is co-prescribed with trimethoprim-sulfamethoxazole (common in CKD patients for infection prophylaxis), dapsone, or rasburicase, all of which can precipitate hemolytic crises in G6PD-deficient individuals. Clinicians prescribing lisinopril to Black male patients should screen for G6PD deficiency before co-initiating these agents.

Dosing Considerations

Lisinopril pharmacokinetics (oral bioavailability 25%, renal elimination, no hepatic metabolism via CYP enzymes) do not differ significantly by ancestry in published studies. Dose adjustment is driven by renal function, not ancestry. Standard dosing ranges apply: 10 to 40 mg/day for hypertension and 5 to 40 mg/day for heart failure, with starting doses of 5 mg/day in patients with CKD (eGFR <30 mL/min per 1.73 m2) 9.

What ancestry does affect is the likelihood of achieving target BP with lisinopril monotherapy. A meta-analysis of 354 randomized antihypertensive trials published in Lancet in 2003 found that ACE inhibitors produced 8 mmHg less systolic BP reduction in Black compared with white patients when used as monotherapy, while diuretics and CCBs showed no significant difference by race 16. Titrating lisinopril to maximum dose before adding a second agent is therefore a less efficient strategy in Black patients than in white patients. Earlier combination therapy is the pragmatic response.

Monitoring and Safety Protocols

Hyperkalemia and Renal Function

ACE inhibitors raise serum potassium by 0.1 to 0.5 mEq/L on average. This risk is amplified in CKD, a condition that disproportionately affects Black Americans (prevalence roughly 16.3% vs. 13.1% in white Americans, per CDC NHANES data) 17. Baseline potassium and creatinine should be checked before starting lisinopril, then repeated at 1 to 2 weeks after initiation and after any dose increase.

Angioedema Counseling Protocol

Given the 3- to 5-fold higher angioedema incidence documented above, the following counseling steps are indicated at every prescribing encounter for Black patients:

1. Describe the symptoms: tongue swelling, lip swelling, throat tightness, or hoarse voice.
2. Emphasize that these can occur months to years after starting the drug.
3. Instruct immediate 911 activation and discontinuation of lisinopril if symptoms arise.
4. Document the counseling in the medical record.

Patients who have experienced ACE-inhibitor angioedema should receive an ARB rather than a different ACE inhibitor if RAAS blockade remains clinically necessary. ARBs do not substantially raise bradykinin levels and carry a much lower angioedema risk, though they are not zero-risk 18.

When to Switch to an ARB

Switching from lisinopril to losartan, valsartan, or irbesartan is appropriate when: (1) ACE-inhibitor cough is intolerable, (2) angioedema has occurred (never rechallenge with any ACE inhibitor after angioedema), or (3) patient preference after informed discussion of the modestly lower BP efficacy of ARBs as monotherapy versus lisinopril in some populations. The 2017 AHA/ACC guideline treats ACE inhibitors and ARBs as therapeutically equivalent for most indications, so switching carries minimal clinical downside 12.

Summary of Evidence-Based Prescribing for Black and African Ancestry Patients

The five core clinical takeaways from the evidence base are:

1. Angioedema risk is 3- to 5-fold higher. Explicit counseling at every initiation visit is mandatory.
2. As monotherapy for uncomplicated hypertension, lisinopril underperforms chlorthalidone and amlodipine. ALLHAT (N=15,080 Black participants) showed a 40% higher stroke rate versus chlorthalidone 10.
3. For proteinuric CKD and HFrEF, lisinopril remains first-line. AASK data showed ACE inhibitors slowed GFR decline more than CCBs or beta-blockers in Black patients with hypertensive CKD 13.
4. Pharmacokinetics are not meaningfully different by ancestry. Dose adjustments should be based on eGFR, not race.
5. Earlier combination therapy (add a thiazide or CCB at initiation or within 4 weeks) is more efficient than up-titrating lisinopril monotherapy in Black patients with uncontrolled hypertension.